(Q45169148)

10 December 2017

1 reference

title

Gefitinib--a novel targeted approach to treating cancer (English)

1 reference

10 December 2017

1

Roy S Herbst

1 reference

10 December 2017

Masahiro Fukuoka

2

1 reference

10 December 2017

José Baselga

series ordinal

3

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

10 December 2017

published in

Nature Reviews Cancer

1 reference

10 December 2017

volume

4

1 reference

10 December 2017

issue

12

1 reference

10 December 2017

page(s)

956-965

1 reference

10 December 2017

cites work

The Hallmarks of Cancer

1 reference

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor

21 January 2018

1 reference

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

21 January 2018

1 reference

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

Extensive experience of disease control with gefitinib and the role of prognostic markers

21 January 2018

1 reference

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

21 January 2018

1 reference

Tolerability of gefitinib in patients receiving treatment in everyday clinical practice

21 January 2018

1 reference

Uncommon presentations of Hodgkin's disease. Case 3. Hodgkin's disease: rectal presentation

21 January 2018

1 reference

Radiation-induced and chemotherapy-induced pulmonary injury

21 January 2018

1 reference

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies

21 January 2018

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer

21 January 2018

1 reference

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

21 January 2018

1 reference

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro

21 January 2018

1 reference

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells

21 January 2018

1 reference

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

Human epidermal growth factor: isolation and chemical and biological properties

21 January 2018

1 reference

Isolation and structure of urogastrone and its relationship to epidermal growth factor

31 March 2020

1 reference

Autocrine secretion and malignant transformation of cells.

31 March 2020

1 reference

Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas

31 March 2020

1 reference

Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients

31 March 2020

1 reference

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

31 March 2020

1 reference

Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma

31 March 2020

1 reference

Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852

31 March 2020

1 reference

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

31 March 2020

1 reference

The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?

31 March 2020

1 reference

Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy

31 March 2020

1 reference

Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

31 March 2020

1 reference

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

31 March 2020

1 reference

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1506

1 reference

Dimensions Publication ID

10 December 2017

1036673500

0 references

1 reference